Vitabin

Quick links to important sections

Vitabin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitabin

What is Vitabin?

Vitabin is a pharmaceutical formulation containing the active substance capecitabine. It belongs to a class of medications known as antimetabolites, which are designed to interfere with the growth and spread of specific types of cells within the body.

Mechanism of Action

Vitabin is an oral prodrug, meaning it is converted into its active form after it is ingested. Once inside the body, the substance undergoes a three-step enzymatic conversion process. The final step of this conversion occurs primarily within tumor tissues, where it is transformed into 5-fluorouracil (5-FU).

As an antimetabolite, the activated form of Vitabin mimics the building blocks of genetic material (DNA and RNA). When cells attempt to incorporate these false building blocks during division, the process is disrupted. This interference prevents the cells from replicating and leads to the eventual cessation of growth in rapidly dividing cell populations.

Therapeutic Use

This medication is primarily utilized in the management of various solid tumors. It is commonly used in the following contexts:

  • Colorectal Cancer: It may be used as a standalone treatment or in combination with other agents for cancer affecting the colon or rectum.
  • Breast Cancer: It is indicated for advanced or metastatic breast cancer, particularly in cases where other treatments have not produced the desired response.
  • Gastric Cancer: It is used as a component of treatment regimens for cancers of the stomach.

Vitabin offers an oral alternative to intravenous therapies, allowing for systemic treatment of the underlying condition. Its use is typically determined based on the specific stage of the disease and the patient's overall health profile.

Regulatory References

  1. Terbinafine: MedlinePlus Drug Information

What side effects are possible with Vitabin?

Possible side effects and safety information

Vitabin (Terbinafine Hydrochloride) is associated with adverse reactions that are classified by frequency and grouped by the organ systems affected, according to official regulatory documents.

Commonly Documented Adverse Reactions

The most frequently listed effects, often classified as Very Common or Common, generally involve the Gastrointestinal system (including diarrhea, nausea, dyspepsia, and abdominal pain), the Nervous System (headache), and the Skin and Subcutaneous Tissue (rash, pruritus, urticaria). Taste disturbance (dysgeusia, hypogeusia), which may be severe, along with joint pain (arthralgia) and muscle pain (myalgia), are also listed as common effects in regulatory labeling.


Serious Adverse Reactions and Safety Constraints

The medicine is associated with documented Serious Adverse Reactions that are classified as Very Rare but clinically significant. These include severe Hepatic Failure (liver injury, sometimes leading to death or transplant) and serious Skin Reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Hematologic effects, including neutropenia and agranulocytosis, are also documented.

Due to the risk of hepatotoxicity, regulatory documents state that the medicine is not recommended for use in patients with pre-existing active or chronic liver disease. Treatment requires monitoring of liver function (LFTs) and must be discontinued if clinical or biochemical evidence of liver injury occurs. Furthermore, specific safety notes state that taste disturbance may be prolonged or permanent following discontinuation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Vitabin (Terbinafine Hydrochloride) defines the clinical profile and mandatory response in cases of acute overdose.


Documented Overdose Manifestations

Following the ingestion of doses significantly exceeding the recommended regimen, regulatory reports suggest a profile primarily involving the gastrointestinal tract and the central nervous system. Documented signs include nausea, vomiting, and abdominal pain, alongside neurological effects such as dizziness and headache. While acute overdose is rarely described as life-threatening, any severe or concerning symptoms must prompt immediate clinical action.


Emergency Actions and Management

The most urgent regulatory instruction is to seek immediate medical attention or contact emergency services immediately upon suspected overdose. Immediate medical evaluation is required when a large dose is known or suspected to have been ingested, or if the affected individual is unresponsive or has difficulty breathing.

Regulatory authorities explicitly state that no specific antidote is known for oral Terbinafine overdose. Therefore, treatment is defined as symptomatic and supportive. This management approach often includes the administration of activated charcoal to remove unabsorbed substance, along with monitoring of vital signs and continuous clinical status observation in a medical facility until the patient is stable.

Therapeutic Uses of Vitabin

What Vitabin Treats: Main Uses and Benefits

The therapeutic role of Vitabin, which generally involves key neurotropic B vitamins, may be part of symptomatic management. This medication is considered relevant for easing discomfort in situations where patients experience symptoms that interfere with daily functioning.

Vitabin is applied across domains where additional symptomatic support is needed, primarily for managing symptoms related to physical discomfort like persistent tingling, numbness, or shooting discomfort, and for addressing symptoms related to systemic imbalance (such as chronic fatigue and generalized weakness). It is also relevant for easing symptoms of poor concentration, 'brain fog', and memory difficulties.

In clinical scenarios, the medicine is commonly used when symptoms intensify and supportive relief is needed, helpful in situations where multiple symptoms occur together. This medication is relevant in contexts involving recurrent or episodic manifestations, assisting with supportive relief that helps ease the overall symptom load and contributes to improved day-to-day comfort.


Quick Fact: Support for Symptoms Related to Discomfort and Fatigue

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Vitabin (Terbinafine Hydrochloride)

This information reflects the official population eligibility and non-eligibility for systemic (oral tablet) Vitabin, as stated in governmental regulatory documents.


Eligibility Scope Status (Official Regulatory Term)
Adults (General Population) Allowed
Chronic or Active Liver Disease Contraindicated
Known Hypersensitivity to Terbinafine Contraindicated
Severe Renal Impairment (CrCl < 50 mL/min) Not Recommended
Breastfeeding Mothers Not Recommended
Pregnant Women Not Recommended (Conditional Use)
Pediatric Patients (Certain Uses) Safety and Effectiveness Not Fully Established
Patients with SLE or Psoriasis Conditional Use (Requires Caution)

Eligibility Classifications (High-Level)

Classification Regulatory Basis
Eligibility Severity Contraindicated (Liver Disease, Hypersensitivity)
Eligibility Context Restrictions primarily apply to the systemic (oral tablet) formulation

Resulting Eligibility Structure

Official eligibility statements detail that the medicine is contraindicated for patients with chronic or active liver disease and those with a history of allergic reaction to the active ingredient. Use is not recommended in populations with severely impaired renal function and breastfeeding women, due to insufficient study data or potential excretion. Eligibility for all other groups is defined by standard use, or conditional use requiring caution, as documented in official prescribing information.

What should I know about interactions with other medicines?

The interaction profile for Vitabin (Terbinafine Hydrochloride) is primarily defined by its effects on metabolic enzymes, as documented in regulatory prescribing information.

Interactions Affecting Other Medicines

Vitabin is officially classified as a moderate to strong inhibitor of the Cytochrome P450 2D6 (CYP2D6) enzyme. Co-administration with other medicines predominantly metabolized by CYP2D6 results in a reduction of their clearance and a subsequent increase in their plasma concentrations. Drug categories affected by this pharmacokinetic interaction include certain Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Beta-blockers, and Type 1C Antiarrhythmics.

Interactions Affecting Vitabin

The systemic exposure of Vitabin itself can be significantly modified by other medicinal products. Co-administration with enzyme inducers, such as Rifampin, is documented to decrease Vitabin's plasma concentration due to a documented increase in its clearance. Conversely, enzyme inhibitors like Cimetidine and Fluconazole may increase Vitabin's exposure.

Population and Administration Context

Use of oral Vitabin is contraindicated in individuals with chronic or active liver disease. This restriction is tied to the reduced clearance of the drug in this population, leading to a risk of increased systemic exposure. Furthermore, regulatory labels specify that co-administration with food does not result in a clinically relevant alteration of Vitabin's systemic exposure. No mandatory timing-based separation rules for administration are documented.

Mechanism of Action

Inhibition of Fungal Ergosterol Biosynthesis

The drug's action centers on the fungal enzyme Squalene Epoxidase, which it inhibits in a non-competitive manner. This enzyme is crucial for synthesizing ergosterol, the primary sterol of the fungal cell membrane. The mechanism confers high specificity for the fungal enzyme, ensuring mammalian systems are largely unaffected.


Dual Mechanism of Fungicidal Action

This enzyme blockade initiates a dual intracellular consequence: a critical deficiency of ergosterol, which compromises membrane structure, and a toxic accumulation of squalene within the fungal cell. This combined biochemical failure severely compromises the pathogen's structure and function, resulting in fungal cell lysis and death (fungicidal action).


Sustained Mechanism in Keratinous Tissues

The active ingredient is characterized by strong lipophilicity, enabling it to rapidly absorb into and persist at high concentrations within skin, hair, and nails (keratinous structures). This accumulation ensures the fungicidal action is continually applied to the deeply embedded pathogens, providing the necessary persistence of the mechanism against the pathogens.

Dosage and Administration Information

Vitabin (Terbinafine Hydrochloride) is administered via the oral route for systemic therapy, specifically targeting infections in the nails. The medicine is also available for topical use (creams or solutions) for localized, external skin fungal conditions. The standard adult systemic regimen involves a single 250 mg dose taken once daily. Treatment duration is fixed based on the infection site: fingernail onychomycosis typically requires 6 weeks, while toenail onychomycosis requires 12 weeks of continuous once-daily dosing.

Intake conditions vary by formulation: the oral tablets may be swallowed with or without food. However, the oral granules designed for specific populations must be mixed entirely with a spoonful of soft, non-acidic food and swallowed immediately, without being chewed. Dosing regimens are once daily, and the dose should preferably be taken at the same time each day. If a dose is missed and the next dose is less than four hours away, the instruction is to skip the missed dose to avoid taking a double dose. Labeling also includes population-specific constraints: the use of systemic Vitabin is generally not recommended in patients with significant chronic liver or kidney impairment, and pediatric dosing is determined using weight-based criteria. This standardized administration protocol defines the appropriate use of the medicine across diverse patient populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Vitabin

This overview summarizes the official clinical research and scientific literature regarding the neurotropic B vitamin combination in Vitabin, focusing only on the types of studies conducted, what they examined, and documented research gaps. This information is purely descriptive and does not provide personal medical advice or treatment recommendations.


Evidence for use in Symptoms Related to Physical Discomfort

Research has evaluated B vitamin combinations in studies exploring symptom variability, specifically focusing on persistent tingling, numbness, and shooting discomfort (peripheral neuropathy). The primary evidence base includes Randomized Controlled Trials (RCTs) and systematic reviews applied to adult populations with various forms of peripheral neuropathy.

Studies monitored how patient-reported outcomes describing perceived discomfort changed in the observed populations across different study groups. Evidence is limited when considering the long-term impact, as follow-up durations were limited, typically lasting only a few months. Evidence quality varies across studies due to differences in formulation and design.


Evidence for use in Symptoms Related to Cognitive Difficulties

Vitabin's components was studied for outcomes related to systemic or functional imbalance affecting cognitive function, such as poor concentration and memory issues. Research in this area includes both RCTs and long-term prospective cohort studies that monitored older adults and individuals identified with mild cognitive impairment.

Research examined the relationship between the B vitamin combination and specific changes in global cognitive function tests and blood biomarkers like homocysteine levels. Findings varied across different studies; for example, large-scale trials have reported inconsistent results regarding global cognitive score changes, especially in populations with normal baseline B vitamin status.


What is Still Uncertain About Vitabin Research

Evidence is limited for generalized, non-specific symptoms like chronic fatigue, where high-quality Randomized Controlled Trials (RCTs) are scarce. A major limitation across the evidence base is the heterogeneity (variability) of the studies, where differences in the specific B vitamin dose or combination used make it difficult to pool and synthesize results consistently. Long-term effects are not fully established for many of the physical discomfort and systemic symptom studies due to limited follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Vitabin (FAQ)

Q: Does Vitabin work immediately or does it need time to build up in the body?

A: Vitabin works by having its active ingredient build up and persist in hard tissues like the skin and nails. Clinical studies suggest that the medicine may start to accumulate and initiate its effect within approximately one to two weeks. However, because the treatment works slowly as these infected tissues grow out, it may take longer for an individual to notice changes in symptoms.

Q: How long does it usually take for a person to notice the expected effect of Vitabin?

A: The time it takes for a person to see a desired result depends on the type and location of the infection. For infections affecting the nails, the medicine works as the healthy nail grows out. Official documents state that a healthy nail may take approximately 12 to 18 months to fully grow out, which is when the maximum benefit is typically assessed.

Q: What is meant by a "serious" side effect of Vitabin?

A: According to regulatory documents, a serious adverse reaction is one that is clinically significant and potentially severe. Examples of these documented effects include serious liver injury (Hepatic Failure), severe skin reactions such as Stevens-Johnson Syndrome (SJS), and certain serious blood disorders. These types of reactions generally require immediate medical assessment.

Q: What is the general frequency of the most commonly listed side effects of Vitabin?

A: Official product information groups side effects based on how frequently they occurred in clinical trials. The most frequently listed effects are classified as Very Common (10% or more) or Common (1% to 10%). These common effects include gastrointestinal issues, headache, and disturbances to the sense of taste.

Q: Are there any known long-term effects associated with using Vitabin?

A: Regulatory documents provide a specific warning that the side effect of taste disturbance may be prolonged, potentially lasting for over a year after stopping treatment. In rare cases, this effect has been described as permanent. Other potential long-term effects are not highlighted in the official regulatory documents in the same manner.

Q: Does Vitabin cause any changes in appetite or weight?

A: Regulatory information indicates that loss of appetite, known as anorexia, is a reported possible effect. Furthermore, the documented loss of taste can occasionally be severe enough to potentially cause a resulting decrease in food intake and subsequent weight loss.

Q: What is the youngest age group for which Vitabin is officially approved?

A: Official prescribing information describes the systemic (oral) formulation as being available for use in children aged 1 year old and over for approved conditions. For children, the appropriate amount of the medicine is typically determined based on the patient's body weight.

Q: What does the term 'contraindication' mean for Vitabin?

A: Contraindication is a strict regulatory term indicating that the medicine is typically not recommended for use due to a high potential risk of harm. Official prescribing information lists conditions such as chronic or active liver disease, or a known allergic reaction to the active ingredient, as contraindications.

Q: How is the body described as processing or eliminating Vitabin (general pharmacokinetics)?

A: After the last dose is taken, the active ingredient leaves the main bloodstream in about 7 days. However, because the medicine is strongly attracted to tissues like the skin and nails, it persists there and is slowly released from these areas over several months.

Q: What are the signs of an allergic reaction to Vitabin?

A: Official documents describe serious allergic reactions (hypersensitivity) as potentially including swelling of the face or throat, hives, or difficulty breathing. Patients may also experience severe skin reactions, such as blistering or peeling.

Q: Are there specific symptoms that warrant calling a doctor immediately while on Vitabin?

A: Official warnings state that patients should be advised to immediately report symptoms that could indicate liver problems. These symptoms include persistent nausea, fatigue, vomiting, pain in the upper abdomen, or signs of jaundice (yellowing of the skin/eyes), dark urine, or pale stools.

Q: How does the body generally react when first starting Vitabin?

A: Clinical studies generally reported that adverse events were often described as mild and transient (temporary). The most common side effects reported when starting the medicine typically include headache, diarrhea, dyspepsia, and abdominal pain.

Q: Is Vitabin considered a treatment or is it mainly used for prevention?

A: The medicine is officially indicated for the treatment of specified fungal infections, such as those affecting the nails (onychomycosis). Its mechanism of action is described as fungicidal, meaning it works to eliminate the fungal pathogen.

Q: Can Vitabin cause changes in sleep patterns?

A: Changes in sleep patterns, specifically trouble falling asleep or staying asleep (insomnia), have been reported during the use of this medicine based on postmarketing experience.

Q: Is it normal to feel a specific side effect like dizziness when starting Vitabin?

A: Dizziness has been reported in postmarketing experience with the medicine. However, its exact frequency is not categorized as common in the official adverse reaction tables.

Q: What are the official recommendations regarding alcohol consumption while using Vitabin?

A: Official patient information often includes guidance to avoid or limit the use of alcohol during the treatment period. This precaution is advised because the medicine is processed primarily by the liver, and alcohol consumption could increase the potential for liver-related side effects.

Q: Can Vitabin be taken with common pain relievers like ibuprofen or acetaminophen?

A: Official patient guidance indicates that, in general, no significant interactions are expected with common over-the-counter pain relievers. This typically includes medicines such as ibuprofen and acetaminophen.

Q: Are there specific herbal supplements or vitamins that are officially listed as interacting with Vitabin?

A: Official guidance notes that there is generally limited data to definitively determine the safety of using all complementary medicines, herbal remedies, and supplements with Vitabin. It is described that some supplements may interfere with how the drug works.

Q: Does Vitabin interact with caffeine?

A: Studies on drug interactions indicate that the medicine can decrease the body's clearance of caffeine. This means the medicine may slow down how quickly the body removes caffeine, which could potentially lead to increased caffeine levels in the system.

Q: Is Vitabin classified as a controlled substance?

A: Vitabin is classified as Not a controlled medication by regulatory agencies. However, the systemic (oral) forms are typically only available via a prescription from a healthcare provider.

Q: Why is a prescription required for Vitabin?

A: The oral forms of the medicine are classified as prescription-only to ensure that patients receive an appropriate medical diagnosis. This restriction also ensures that patients can be properly monitored by a healthcare provider for the potential risk of serious adverse reactions, such as liver problems.

Q: Why do some people on forums say Vitabin affects their energy levels?

A: The official safety information lists loss of energy or unusual tiredness and weakness among the possible side effects reported by patients. This may be the reason some individuals discuss changes in energy levels while taking the medicine.

Q: Are there any known interactions between Vitabin and birth control pills?

A: Official information suggests that the medicine is not expected to affect the efficacy (effectiveness) of combined oral contraceptives. However, some cases reporting menstrual irregularities, such as breakthrough bleeding, have been documented.

How should Vitabin be stored and disposed of?

The storage and disposal of Vitabin (Terbinafine HCl) must strictly follow the conditions defined in official regulatory labeling to maintain potency and safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect from moisture and light. Do not refrigerate or freeze.
Container Keep the medicine in the original container and ensure it is tightly closed.

Stability and Safety

Vitabin must not be used past the expiration date on the label. All forms of the medicine must be kept out of the sight and reach of children.

Disposal Requirements

Expired or unused Vitabin must be discarded according to local requirements, preferably through a drug take-back program. The product should not be flushed down a toilet or poured into a drain unless specifically instructed by official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitabin found in:

A-Z Index: